Avadel Pharmaceuticals (NASDAQ: AVDL)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-07 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-09 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Avadel Pharmaceuticals (NASDAQ: AVDL) through any online brokerage.
Other companies in Avadel Pharmaceuticals’s space includes: Aerie Pharmaceuticals (NASDAQ:AERI), Verona Pharma (NASDAQ:VRNA), WAVE Life Sciences (NASDAQ:WVE), CymaBay Therapeutics (NASDAQ:CBAY) and ANI Pharmaceuticals (NASDAQ:ANIP).
The latest price target for Avadel Pharmaceuticals (NASDAQ: AVDL) was reported by Needham on Tuesday, May 31, 2022. The analyst firm set a price target for 6.00 expecting AVDL to fall to within 12 months (a possible -4.91% downside). 5 analyst firms have reported ratings in the last year.
The stock price for Avadel Pharmaceuticals (NASDAQ: AVDL) is $6.31 last updated August 8, 2022, 8:00 PM UTC.
There are no upcoming dividends for Avadel Pharmaceuticals.
Avadel Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 7, 2022.
There is no upcoming split for Avadel Pharmaceuticals.
Avadel Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.